文献速递妇科

新诊断上皮性卵巢癌女性腹股沟淋巴结转移的发生率及预后意义

Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2022-03-07

这项回顾性单机构队列研究纳入2009至2017年562例III/IV期上皮性卵巢癌患者,18例(3.2%)诊断时存在腹股沟淋巴结转移。腹股沟淋巴结转移未显著影响无进展生存期和总生存期,但达到无肉眼残留病灶的切除与无进展生存期改善相关。

要点

  • 晚期上皮性卵巢癌诊断时腹股沟淋巴结转移发生率为3.2%(18/562)。
  • 腹股沟淋巴结转移组与无转移组相比,无进展生存期和总生存期无显著差异。
  • 腹股沟淋巴结转移患者中,达到无肉眼残留病灶切除者无进展生存期优于非最佳切除者。

核心结论

  • 在该回顾性队列研究中,3.2%的晚期上皮性卵巢癌女性诊断时存在腹股沟淋巴结转移。
  • 腹股沟淋巴结转移与分别比较的所有III/IV期和IVB期患者相比,未预示更差的临床结局。
  • 切除至无肉眼残留病灶与无进展生存期改善相关。

研究设计与样本

  • 经IRB批准的回顾性单机构队列研究,纳入2009至2017年III/IV期上皮性卵巢癌女性。
  • 通过临床或影像学识别腹股沟淋巴结肿大(定义为短轴>1 cm)的患者。
  • 评估腹股沟淋巴结转移对无进展生存期和总生存期的影响。

主要发现

  • 562例晚期上皮性卵巢癌女性中,18例(3.2%)诊断时存在腹股沟淋巴结转移,占所有IVB期患者(n=70)的25.7%。
  • 5例(27.7%)存在已知的上皮性卵巢癌遗传易感,包括BRCA1(11.1%,n=2)、BRCA2(11.1%,n=2)和BRIP1(5.6%,n=1)。
  • 大多数患者接受最佳初次肿瘤细胞减灭术(83.3%,n=15),包括腹股沟淋巴结转移灶减灭,其中50%(n=9)术后无肉眼残留病灶。
  • 腹股沟淋巴结转移的III/IV期患者、无腹股沟淋巴结转移的III/IV期患者和无腹股沟淋巴结转移的IVB期患者,无进展生存期分别为19.9、19.9和17.2个月(p=0.84),总生存期分别为137.2、52.9和67.6个月(p=0.29),均无差异。
  • 腹股沟淋巴结转移患者中,最佳切除至无肉眼病灶者对比非最佳切除者,无进展生存期分别为27.4和14.3个月(p=0.019);总生存期分别为137.2和57.3个月(p=0.24),未达统计学显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To assess incidence and oncologic outcomes in women with advanced epithelial ovarian cancer (EOC) with inguinal lymph node metastasis (ILNM) at diagnosis. METHODS: An IRB-approved, retrospective single-institution cohort study was performed in women with stage III/IV EOC from 2009 to 2017. Patients with inguinal lymphadenopathy (defined as >1 cm in short axis) clinically or radiographically were identified. The impact of ILNM on progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: Of the 562 women with advanced EOC, 18 (3.2%) had ILNM at diagnosis, accounting for 25.7% of all patients with stage IVB disease (n = 70). Five patients (27.7%) had a known genetic predisposition for EOC, including BRCA1 (11.1%, n = 2), BRCA2 (11.1%, n = 2) and BRIP1 (5.6%, n = 1). The majority of patients underwent optimal primary cytoreductive surgery (CRS), including debulking of inguinal nodal metastasis (83.3%, n = 15), with 50% (n = 9) having no gross residual disease after surgery. There was no difference in PFS (19.9 vs. 19.9 vs. 17.2 months, p = 0.84) or OS (137.2 vs. 52.9 vs. 67.6 months, p = 0.29) in women with stage III/IV with ILNM, stage III/IV without ILNM, and stage IVB disease without ILNM, respectively. Progression-free survival was improved in women with ILNM who underwent an optimal resection to no macroscopic disease vs. non-optimal resection (27.4 vs. 14.3 months, p = 0.019). Median overall survival at the time of analysis did not reach statistical significance (137.2 vs. 57.3 months, p = 0.24). CONCLUSION(S): In this retrospective cohort study, 3.2% of women with advanced EOC presented with ILNM at diagnosis. Although ILNM did not portend worse clinical outcomes compared to all Stage III/IV and Stage IVB patients, respectively, resection to no gross residual disease was associated with improved PFS.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chalif J, Yao M, Gruner M, et al. Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 35272875. doi:10.1016/j.ygyno.2022.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。